Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PET

British Journal of Cancer

Volumn 86, Issue 4, 2002, Pages 506-511

  Bokemeyer, Carsten ^a   Kollmannsberger, C ^a   Oechsle, K ^a   Dohmen, B M ^a   Pfannenberg, A ^a   Claussen, C D ^a   Bares, R ^a   Kanz, L ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Germ cell cancer; High dose chemotherapy; PET; Response monitoring; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LACTATE DEHYDROGENASE; PACLITAXEL; THIOTEPA; TUMOR MARKER;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SALVAGE THERAPY; SEMINOMA; SENSITIVITY AND SPECIFICITY; TESTICULAR NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037065953     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600122     Document Type: Article

References (33)

1. Treatment for poor prognosis metastatic germ-cell tumours: Much heat but, yet, little light
2. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables
3. High-dose versus conventional-dose first-salvage treatment in nonseminoma: A matched-pair analysis
4. High-dose chemotherapy with peripheral stem cell or autologous bone marrow transplant as initial salvage chemotherapy for testicular cancer
5. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors
6. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer
7. FDG PET for detection and therapy control of metastatic germ cell tumor
8. Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma
9. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumors: An effective first-line therapy with minimal toxicity
10. Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
11. Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: A study in patients with disseminated non-seminomatous testicular cancer
12. Treatment of testicular cancer: A new and improved model
13. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
14. Additional value of wholebody positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer
15. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma
16. Diagnosis and treatment of patients with testicular germ cell cancer
17. Quantitating tumor glucose metabolism with FDG and PET
18. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer
19. 18F]-FDG PET with conventional assessment by CT scans and serum tumor markers for the evaluation of residual masses in non-seminomatous germ cell cancer patients
20. Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction
21. FDG-PET in the prediction of survival of patients with cancer of the pancreas: A pilot study
22. International Germ Ceil Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers
23. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors
24. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity
25. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stell cell rescue in patients with relapsed or refractory germ cell cancer
26. High-dose salvage chemotherapy. Germ cell tumor treatment results in Germany
27. 18F]-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
28. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
29. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients
30. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients
31. The applications of PET in clinical oncology
32. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
33. Management strategies and outcomes of germ cell tumor patients with very high human chorionic gonadotropin levels